Literature DB >> 9247483

The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome.

M B Fallon1, G A Abrams, B Luo, Z Hou, J Dai, D D Ku.   

Abstract

BACKGROUND & AIMS: The hepatopulmonary syndrome occurs when intrapulmonary vasodilatation causes impaired arterial gas exchange in liver disease. The pathogenesis is poorly understood, although nitric oxide may be involved. Common bile duct ligation in the rat is a model of the hepatopulmonary syndrome, but no studies have evaluated NO in pulmonary vasodilatation in this model. The aim of this study was to determine whether NO contributes to intrapulmonary vasodilatation after bile duct ligation.
METHODS: Endothelial and inducible NO synthase (NOS) levels and localization and NO activity in pulmonary artery rings were assessed after bile duct ligation.
RESULTS: Pulmonary endothelial NOS levels increased and alveolar vascular staining was enhanced after bile duct ligation. No change in pulmonary inducible NOS levels or localization was detected. Increased endothelial NOS levels correlated with alterations in gas exchange and were accompanied by enhanced NO activity and a blunted response to phenylephrine, reversible by NOS inhibition, in pulmonary artery rings. Portal-vein-ligated animals, which do not develop intrapulmonary vasodilatation, had no changes in pulmonary NOS production or in NO activity in pulmonary artery rings.
CONCLUSIONS: NO, derived from pulmonary vascular endothelial NOS, contributes to intrapulmonary vasodilation in animal hepatopulmonary syndrome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247483     DOI: 10.1053/gast.1997.v113.pm9247483

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  46 in total

1.  Hepatopulmonary syndromes.

Authors:  M J Krowka
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 2.  Hepatopulmonary syndrome.

Authors:  M B Fallon; G A Abrams
Journal:  Curr Gastroenterol Rep       Date:  2000-02

3.  Pathogenesis of pulmonary arteriovenous malformations: role of hepatopulmonary interactions.

Authors:  J J Vettukattil
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

4.  Pulmonary complications of cirrhosis.

Authors:  Rajan Kochar; Moises I Nevah Rubin; Michael B Fallon
Journal:  Curr Gastroenterol Rep       Date:  2011-02

5.  The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.

Authors:  Wenli Yang; Junlan Zhang; Bingqian Hu; Wei Wu; Julie Venter; Gianfranco Alpini; Michael B Fallon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-07       Impact factor: 4.052

Review 6.  [Pulmonary complications in liver diseases].

Authors:  T Horvatits; A Drolz; K Rutter; S Kluge; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-26       Impact factor: 0.840

7.  Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease.

Authors:  Kari E Roberts; Steven M Kawut; Michael J Krowka; Robert S Brown; James F Trotter; Vijay Shah; Inga Peter; Hocine Tighiouart; Nandita Mitra; Elizabeth Handorf; James A Knowles; Steven Zacks; Michael B Fallon
Journal:  Gastroenterology       Date:  2010-03-24       Impact factor: 22.682

Review 8.  Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.

Authors:  Sarah Raevens; Michael B Fallon
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

9.  Pilot study of pentoxifylline in hepatopulmonary syndrome.

Authors:  Rajasekhar Tanikella; George M Philips; Dorothy K Faulk; Steven M Kawut; Michael B Fallon
Journal:  Liver Transpl       Date:  2008-08       Impact factor: 5.799

Review 10.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.